Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

A 3-Year Prospective Cohort Study on 132 Calcium Phosphate-Blasted Implants: Flap vs Flapless Technique.

Prati C, Zamparini F, Scialabba VS, Gatto MR, Piattelli A, Montebugnoli L, Gandolfi MG.

Int J Oral Maxillofac Implants. 2016 Mar-Apr;31(2):413-23. doi: 10.11607/jomi.4623.

PMID:
27004288
2.

Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.

Groeneweg JW, Hernandez SF, Byron VF, DiGloria CM, Lopez H, Scialabba V, Kim M, Zhang L, Borger DR, Tambouret R, Foster R, Rueda BR, Growdon WB.

Clin Cancer Res. 2014 Dec 15;20(24):6517-6528. doi: 10.1158/1078-0432.CCR-14-1647. Epub 2014 Oct 7.

3.

Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment.

Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, Scialabba VL, Batten JM, Borger DR, Iafrate AJ, Heist RS, Lawrence DP, Flaherty KT, Bendell JC, Deschler D, Li Y, Wirth LJ, Dias-Santagata D.

Clin Cancer Res. 2013 Jan 15;19(2):480-90. doi: 10.1158/1078-0432.CCR-12-1842. Epub 2012 Nov 27.

4.

Activation of PI3K signaling in Merkel cell carcinoma.

Nardi V, Song Y, Santamaria-Barria JA, Cosper AK, Lam Q, Faber AC, Boland GM, Yeap BY, Bergethon K, Scialabba VL, Tsao H, Settleman J, Ryan DP, Borger DR, Bhan AK, Hoang MP, Iafrate AJ, Cusack JC, Engelman JA, Dias-Santagata D.

Clin Cancer Res. 2012 Mar 1;18(5):1227-36. doi: 10.1158/1078-0432.CCR-11-2308. Epub 2012 Jan 18.

5.

Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin.

Growdon WB, Roussel BN, Scialabba VL, Foster R, Dias-Santagata D, Iafrate AJ, Ellisen LW, Tambouret RH, Rueda BR, Borger DR.

Gynecol Oncol. 2011 Apr;121(1):212-7. doi: 10.1016/j.ygyno.2010.11.039. Epub 2010 Dec 17.

PMID:
21168197

Supplemental Content

Loading ...
Support Center